- 101. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 56-62 and 64-70 of SEQ ID NO: 39 and amino acid 63 56 of SEQ ID NO: 39 is substituted with a valine.
- 102. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 56-64 and 66-70 of SEQ ID NO: 39 and amino acid 65 56 of SEQ ID NO: 39 is substituted with a valine.
- 103. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 448-450 and 452-462 of SEQ ID NO: 39 and amino acid 451 of SEQ ID NO: 39 is substituted with a phenylalanine.
- 104. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of amino acids 448-455 and 457-462 of SEQ ID NO: 39 and amino $\frac{1}{2}$ (I) acid 456 of SEQ ID NO: 39 is substituted with a valine.
- 105. (New) The immunogenic peptide of claim 100, wherein the peptide consists essentially of 450-455 and 457-462 of SEQ ID NO: 39 and amino acid 456 is substituted with a valine.
- 106. (New) The immunogenic peptide of claim 100, wherein the peptide is a peptide selected from the group consisting of:
 - (A) a peptide consisting essentially of amino acids 56, 57, and 59-70 of SEQ ID NO: 39 and amino acid 58 of SEQ ID NO: 39 is substituted with a phenylal anine or a valine; and
 - (B) a peptide consisting essentially of amino acids 448 and 450-462 of SEQ ID NO: 39 and amino acid 449 of SEQ ID NO: 39 is substituted with a phenylalanine or a glutamine;
- 107. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 56-70 of SEQ ID NO: 39.
- 108. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 448-462 of SEQ ID NO: 39.

- 109. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 57-70 of SEQ ID NO: 39.
- 110. The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 449-462 of SEQ ID NO: 39.
- 111. (New) The isolated immunogenic peptide of claim 100, wherein the peptide consists of amino acids 450-462 of SEQ ID NO: 39.
- 112. (New) The immunogenic peptide of claim 100, wherein the MHC Class II molecule is Human Leukocyte Antigen (HLA)-DR.
- 113. (New) The immunogenic peptide of claim 112, wherein the HLA-DR is HLA-DRB1*0401.
- 114. (New) The immunogenic peptide of claim 100 linked to an MHC Class II molecule, or a portion thereof.
- 115. (New) The immunogenic peptide of claim 114, wherein the portion of the MHC Class II molecule is the β chain of the MHC Class II molecule.
 - 116. (New) A composition comprising an immunogenic peptide of claim 100
 - 117. (New) A composition comprising an immunogenic peptide of claim 114.
- 1/18. (New) A method of inducing CD4⁺ T lymphocytes to respond to melanoma, which method comprises:
 - (i) contacting antigen presenting cells with a composition of claim 116 in vitro, and
 - (ii) simultaneously or subsequently exposing CD4⁺ T lymphocytes to the antigen presenting cells *in vitro*,

whereupon the CD4⁺ T lymphocytes are induced to respond to melanoma.

- 1/19. (New) The method of claim 118, wherein the CD4⁺ T lymphocytes are obtained from a host and the method further comprises:
 - (iii) administering the CD4⁺ T lymphocytes to the host.

- 120. (New) The method of claim 119, wherein the host is a mammal.
- 121. (New) The method of claim 120, wherein the mammal is a human.
- 122. (New) The method of claim 119, wherein the antigen presenting cells are obtained from the host.
- 123. (New) A method of inducing CD4⁺ T lymphocytes in a host to respond to melanoma, which method comprises:
 - (i) contacting antigen presenting cells with a composition of claim 116 in vitro, and
 - (ii) subsequently exposing CD4⁺ T lymphocytes in the host to the antigen presenting cells by administering the antigen presenting cells to the host,

whereupon the CD4⁺T lymphocytes in the host are induced to respond to melanoma.

- 124. (New) The method of claim 123, wherein the host is a mammal.
- 125. (New) The method of claim 124, wherein the mammal is a human.
- 126. (New) The method of claim 123, wherein the antigen presenting cells are obtained from the host.
- (New) A method of inducing CD4⁺ T lymphocytes in a host to respond to melanoma, which method comprises administering the composition of claim 116 to the host, whereupon the CD4⁺ T lymphocytes in the host are induced to respond to melanoma.
- (New) A method of inducing CD4⁺ T lymphocytes to respond to melanoma, which method comprises:
 - (i) contacting antigen presenting cells with a composition of claim 117/in vitro, and
 - (ii) simultaneously or subsequently exposing CD4⁺ T lymphocytes to the antigen presenting cells *in vitro*,

whereupon the CD4⁺ T lymphocytes are induced to respond to melanoma.

- 129. (New) The method of claim 128, wherein the CD4⁺ T lymphocytes are obtained from a host and the method further comprises:
 - (iii) administering the CD4⁺ T lymphocytes to the host.
 - 130. (New) The method of claim 129, wherein the host is a mammal.
 - 131. (New) The method of claim 130, wherein the mammal is a human.
- 132. (New) The method of claim 128, wherein the antigen presenting cells are obtained from the host.
- 133. (New) A method of inducing CD4⁺ T lymphocytes in a host to respond to melanoma, which method comprises:
 - (i) contacting antigen presenting cells with a composition of claim 117 in vitro, and
 - (ii) subsequently exposing CD4⁺ T lymphocytes in the host to the antigen presenting cells by administering the antigen presenting cells to the host,

whereupon the CD4⁺T lymphocytes in the host are induced to respond to melanoma.

- 134. (New) The method of claim 133, wherein the host is a mammal.
- 135. (New) The method of claim 134, wherein the mammal is a human.
- 136. (New) The method of claim 133, wherein the antigen presenting cells are obtained from the host.
- 137. (New) A method of inducing CD4⁺ T lymphocytes in a host to respond to melanoma, which method comprises administering the composition of claim 117 to the host, whereupon the CD4⁺ T lymphocytes in the host are induced to respond to melanoma.

/x1 couls